Implementation of the Pharmaceutical Industry Development “15th Five-Year Plan” and Standout Data for Domestic Novel Drugs at WCLC: Chinaamc Hang Seng Hong Kong Biotech Index ETF (03069.HK) Rose 10.82%
- The Pharmaceutical Industry Development “15th Five-Year Plan” targets the biopharmaceutical industry becoming a national emerging pillar industry by 2030, with first-in-class (FIC) drugs accounting for more than 25% of the global total, innovative drug approvals ranking among the world's highest, and AI empowering drug R&D.
- At the World Conference on Lung Cancer held from 12 to 15 September, HANSOH PHARMA's B7-H3-targeted ADC met the primary OS endpoint in a Phase III trial with a median OS of 18.5 months, nearly double the control group, and AKESO's ivonescimab showed significantly positive OS in the HARMONi-2 study.
- Eight outbound BD deals for innovative drugs were completed in August with a total potential value of about USD 6 billion; Novo Nordisk partnered with Anthropic, and GENSCRIPT BIO formed an AI drug discovery collaboration with Eli Lilly's TuneLab.
NewTimeSpace News:As of 18 September, ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (03069.HK) gained 10.82% year-to-date and 7.21% over the past six months, while the Hang Seng Index fell 3.43% and 4.90% over the same periods and peer funds rose only 2.81% and 2.88%; over the past year the ETF declined 9.84% but still outperformed its underlying index by about 0.4 percentage points. Over a longer horizon, it gained 96.02% over the past two years, beating the Hang Seng Index by about 56 percentage points and its underlying index by about 1 percentage point, and rose 53.90% over the past three years, beating the Hang Seng Index by about 15.9 percentage points.
Among its constituents, GENSCRIPT BIO led the gains with a 5.70% jump on 18 September, WUXI APPTEC rose 1.01% and CSPC PHARMA gained 0.90%, while AKESO edged down 0.28%, reflecting the sector's sharp long-cycle volatility.
Positive news flow: on 18 September, the Ministry of Industry and Information Technology, together with nine other departments, jointly issued the Pharmaceutical Industry Development “15th Five-Year Plan”, which calls for the biopharmaceutical industry to accelerate into a national emerging pillar industry by 2030, with first-in-class (FIC) novel drugs accounting for more than 25% of the global total, the number of approved innovative drugs ranking among the highest in the world, and AI empowering drug R&D; the National Healthcare Security Administration is piloting a pre-approval pricing mechanism for high-level new-technology medical service items, seamlessly linking innovation approval with price setting.
At the World Conference on Lung Cancer (WCLC) held from 12 to 15 September, HANSOH PHARMA's B7-H3-targeted ADC met the primary overall survival (OS) endpoint in its Phase III trial (median OS of 18.5 months, nearly double that of the control group), while AKESO's ivonescimab showed significantly positive OS results in the HARMONi-2 study.
In August, eight outbound business development (BD) deals for innovative drugs were completed, with a total potential value of about USD 6 billion; Novo Nordisk partnered with Anthropic, and GENSCRIPT BIO entered into an AI-driven drug discovery collaboration with Eli Lilly's TuneLab.
The ETF tracks the Hang Seng Hong Kong-Listed Biotech Index, compiled by Hang Seng Indexes Company Limited, covering biotechnology companies listed in Hong Kong and, through the Hong Kong Stock Exchange's Chapter 18A regime, including pre-profit biotech companies, thereby capturing in advance China's most innovation-driven biomedical front-runners. It also covers leading CXO companies, providing a “CXO + innovative drugs” dual-engine exposure; with ample order backlogs and resilient earnings, CXOs give the index broader industry-chain coverage than pure innovative-drug indices. The product carries a fee ratio of 0.64% and has been listed for more than five years with a mature track record.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
